Home Alzheimer’s Disease Survival Advantage Is Experienced by Patients Receiving Apalutamide Added to ADT for...

Survival Advantage Is Experienced by Patients Receiving Apalutamide Added to ADT for mCSPC

A 35% reduction in the risk of death with apalutamide (Erleada) was seen versus placebo in patients receiving androgen-deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC), according to data from the final analysis of the phase 3 randomized, double-blind, placebo-controlled TITAN trial (NCT02489318).

In the trial, 1052 patients with mCSPC were randomized 1:1 to receive apalutamide plus ADT or placebo plus ADT. Dual primary end points were radiographic progression-free survival (rPFS) and overall survival (OS), according to investigator Kim N. Chi, MD, chief medical officer and vice president of BC Cancer, Vancouver, Canada, who presented the findings at the 2021 Genitourinary Cancers Symposium.

For the TITAN trial (NCT02489318), 1052 patients with mCSPC were randomized 1:1 to receive apalutamide plus ADT or placebo plus ADT. Dual primary end points were…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments